Companies Dominating the Medication-assisted Treatment Landscape
- Indivior PLC
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mallinckrodt Pharmaceuticals
- Titan Pharmaceuticals, Inc.
- Alkermes plc
- Orexo AB
- Mylan N.V.
- Teva Pharmaceuticals Industries Ltd.
- Lupin limited
- Hikma Pharmaceuticals PLC
- Novartis AG
Browse Key Market Insights with Data Illustration:
In the News
- December 2023: Alkerems plc announced that it entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk , a leading global healthcare company. In terms of agreement, Alkermes will be entitled to one time cash payment of USD 92.5 Million for the facility and related assets, subject to customary adjustments in accordance with the agreement. In addition, Alkermes and Novo Nordisk also plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing the transaction, which may continue through the end of 2025.
- August 2023: Orexo AB announced that it continues to strengthen its patent portfolio and the new patent , No. US 11,737,980 provides protection for the OX640 product in the US until may 2041. Moreover, Orexo’s proprietary drug delivery platform , amorphOX, is a powder made up of particles which are built using a unique combination of drug, carrier materials and optionally other ingredients.
